These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15892675)

  • 1. Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs.
    Akarca US
    Curr Pharm Des; 2005; 11(14):1779-93. PubMed ID: 15892675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention.
    Ballinger A; Smith G
    Expert Opin Pharmacother; 2001 Jan; 2(1):31-40. PubMed ID: 11336566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
    Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
    JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of COX-2 inhibitors in common clinical practice a gastroenterologist's perspective.
    Lehmann FS; Beglinger C
    Curr Top Med Chem; 2005; 5(5):449-64. PubMed ID: 15974940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury.
    Griffin MR
    Am J Med; 1998 Mar; 104(3A):23S-29S; discussion 41S-42S. PubMed ID: 9572317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal antiinflammatory drugs and cyclooxygenase inhibition in the gastrointestinal tract: a trip from peptic ulcer to colon cancer.
    Lanas A
    Am J Med Sci; 2009 Aug; 338(2):96-106. PubMed ID: 19680014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective COX-2 inhibitors: a health economic perspective.
    Schwappach DL; Koeck CM
    Wien Med Wochenschr; 2003; 153(5-6):116-22. PubMed ID: 12705064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [NSAIDs and its gastrointestinal side effects: relation of NSAIDs variety and influence of concomitant medicine].
    Iwakiri R
    Nihon Rinsho; 2007 Oct; 65(10):1776-80. PubMed ID: 17926523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.
    Cryer B; Feldman M
    Am J Med; 1998 May; 104(5):413-21. PubMed ID: 9626023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors.
    Laine L
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):25-32. PubMed ID: 12528071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease: pathophysiology, treatment and prevention.
    Bjorkman DJ; Kimmey MB
    Dig Dis; 1995; 13(2):119-29. PubMed ID: 7586632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in managing NSAID-associated gastrointestinal tract injury.
    Goldstein JL
    Digestion; 2004; 69 Suppl 1():25-33. PubMed ID: 15001832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Laine L; Curtis SP; Cryer B; Kaur A; Cannon CP;
    Lancet; 2007 Feb; 369(9560):465-73. PubMed ID: 17292766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-inflammatory effect and low ulcerogenic activity of etodolac, a cyclooxygenase-2 selective non-steroidal anti-inflammatory drug, on adjuvant-induced arthritis in rats.
    Tachibana M; Inoue N; Yoshida E; Matsui M; Ukai Y; Yano J
    Pharmacology; 2003 Jun; 68(2):96-104. PubMed ID: 12711837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.